| P50 | author | Jianrong Zhang | Q55979518 |
| P2093 | author name string | Jieyu Wu | |
| | Qihua He | |
| | Jianxing He | |
| | Wenhua Liang | |
| P2860 | cites work | Projections of global mortality and burden of disease from 2002 to 2030 | Q21144688 |
| | Cellular and molecular mechanisms of metformin: an overview | Q27013561 |
| | Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis | Q27025309 |
| | Global cancer statistics, 2012 | Q27860501 |
| | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860868 |
| | Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung | Q28208680 |
| | Cyclooxygenase-2 and carcinogenesis | Q33866664 |
| | Metformin induces apoptosis through AMPK-dependent inhibition of UPR signaling in ALL lymphoblasts | Q34979869 |
| | Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy | Q35149589 |
| | Survival of patients with stage IV lung cancer with diabetes treated with metformin | Q35153493 |
| | Association of the metformin with the risk of lung cancer: a meta-analysis | Q35200421 |
| | Impact of metformin use on survival in locally-advanced, inoperable non-small cell lung cancer treated with definitive chemoradiation | Q35290403 |
| | Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis | Q35333423 |
| | Effects of metformin on survival outcomes of lung cancer patients with type 2 diabetes mellitus: a meta-analysis | Q35803926 |
| | Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer | Q36103093 |
| | Metformin therapy associated with survival benefit in lung cancer patients with diabetes | Q37376577 |
| | The new lung cancer staging system | Q37543784 |
| | A Multicenter Double-blind Phase II Study of Metformin With Gefitinib as First-line Therapy of Locally Advanced Non-Small-cell Lung Cancer | Q38382675 |
| | Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes | Q40571611 |
| | Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy | Q40919306 |
| | The Clinical Effect of Metformin on the Survival of Lung Cancer Patients with Diabetes: A Comprehensive Systematic Review and Meta-analysis of Retrospective Studies | Q41242882 |
| | Metformin and lung cancer risk of patients with type 2 diabetes mellitus: A meta-analysis | Q41303279 |
| | Metformin Addition to Chemotherapy in Stage IV Non-Small Cell Lung Cancer: an Open Label Randomized Controlled Study. | Q53322434 |
| | AMP-activated protein kinase mediates T cell activation-induced expression of FasL and COX-2 via protein kinase C theta-dependent pathway in human Jurkat T leukemia cells | Q83435153 |
| | Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes | Q83979505 |
| P433 | issue | 3 | |
| P921 | main subject | metformin | Q19484 |
| | systematic review | Q1504425 |
| P304 | page(s) | 389-396 | |
| P577 | publication date | 2018-06-01 | |
| P1433 | published in | Translational lung cancer research | Q26842616 |
| P1476 | title | The prognostic value of metformin for advanced non-small cell lung cancer: a systematic review and meta-analysis | |
| P478 | volume | 7 | |